Selecting a Contract Research Organisation (CRO) is one of the most consequential decisions a sponsor will make during clinical development. Whether you are a biotech entering First-in-Human studies or a pharmaceutical company progressing into Phase III, the right CRO can improve operational control and reduce development risk.
Understanding how to choose a CRO requires more than reviewing capability brochures. It demands a structured evaluation of expertise, infrastructure, therapeutic alignment and critically, CRO project management capability.
Below are the key factors sponsors should assess when selecting a CRO partner.
Key Areas to Consider When Choosing CRO Project Management
1. Define What You Actually Need
Before approaching vendors, clarify the scope of support required.
Do you need:
- Full-service clinical trial delivery?
- Stand-alone biometrics or data management?
- Early-phase clinical pharmacology expertise?
- Regulatory or pharmacovigilance support?
- Central laboratory or specialist imaging services?
A CRO should align with your operational model. Some sponsors require full integration from Phase I to Phase III. Others need specialist support layered onto existing infrastructure.
Simbec-Orion provides flexible, full-service CRO services, supporting clinical management from Phase I to Phase III as well as stand-alone specialist functions including biometrics, pharmacovigilance, regulatory affairs and clinical pharmacology. Understanding whether a CRO can adapt to your structure is central to choosing the right partner.
2. Assess Therapeutic and Phase-Specific Expertise
Experience in your therapeutic area significantly reduces operational risk. Reviewing a CRO’s therapeutic expertise across Phase I–III studies can provide insight into their familiarity with your indication and study complexity.
For example:
- Oncology and rare disease trials require specialist site networks.
- CNS studies may require access to advanced neuroscience tools.
- Early-phase studies demand intensive safety oversight and dose-escalation experience.
Sponsors should request concrete examples of similar trials, including indication, patient population, geography and regulatory environment.
Phase-specific experience is equally important. Early-phase units must demonstrate strong safety governance and rapid data interpretation. Later-phase trials demand robust site management and scalable infrastructure. When evaluating how to choose a CRO, proven experience in your study type should be a non-negotiable criterion.
3. Evaluate CRO Project Management Structure
Strong CRO project management is often the defining factor in trial success. Effective CRO project management ensures coordination across biometrics, clinical operations, pharmacovigilance, regulatory affairs and laboratory services. It also determines how quickly issues are identified and mitigated.
A well-structured project management framework should include. Defined governance processes, Transparent reporting dashboards and Proactive risk identification.
Without strong project leadership, even technically capable CROs may struggle to deliver consistently.
4. Review Infrastructure and Operational Integration
A CRO’s infrastructure should match the complexity of your programme.
This means evaluating the strength and depth of its clinical operations teams, data management and biostatistics capability, IMP management processes, pharmacovigilance systems, regulatory affairs expertise and overall quality assurance oversight. Each of these functions plays a critical role in maintaining control, compliance and operational efficiency throughout the study lifecycle.
Sponsors should assess whether these services are delivered internally or outsourced, as the level of integration directly affects communication flow and speed of decision-making. Integrated delivery models often improve efficiency and reduce fragmentation across workstreams.
5. Examine Quality and Regulatory Track Record
Quality assurance and regulatory compliance underpin every successful clinical trial.
Sponsors should consider:
- Recent audit outcomes
- Inspection history
- SOP frameworks
- Data integrity controls
- GCP compliance processes
A CRO’s experience working with agencies such as MHRA, EMA and FDA is particularly valuable when planning global development programmes. The right partner will not only comply with regulations but also proactively anticipate regulatory expectations.
6. Consider Agility and Cultural Fit
Size is not always the defining factor in CRO selection.
Large global CROs offer scale. Smaller or mid-sized CROs often provide:
- Greater agility
- Direct access to senior leadership
- Faster decision-making
- More personalised sponsor engagement
Sponsors should evaluate communication style, responsiveness and willingness to adapt. Cultural alignment can influence collaboration as much as technical capability.
When determining how to choose a CRO, operational chemistry matters alongside credentials.
7. Look Beyond Cost Alone
While budget is critical, the lowest bid rarely represents the lowest overall risk.
Sponsors should evaluate:
- Transparency of cost structure
- Assumptions underlying timelines
- Contingency planning
- Scope flexibility
Delays due to poor CRO project management or limited experience often result in higher long-term costs than selecting a more capable partner at the outset.
Making a Strategic CRO Selection
Choosing a CRO is ultimately about partnership. The right organisation should function as an extension of your internal team, combining therapeutic insight and structured CRO project management.
For pharma and biotech developers navigating complex development pathways, selecting the appropriate CRO can determine whether milestones are met efficiently or delayed by avoidable friction. Understanding how to choose a CRO means looking beyond marketing claims and evaluating delivery capability, governance structure and alignment with your programme objectives.
If you are assessing CRO partners for an upcoming clinical programme, exploring an organisation’s full-service capabilities, therapeutic expertise and integrated infrastructure is a strong place to start.
Simbec-Orion as your Expert CRO
Partner with Simbec-Orion for a comprehensive portfolio of trials. As a responsive full-service CRO, we deliver clinical studies from first-in-human through to Phase III, with the precision and commitment your programme deserves. Our knowledgeable teams combine broad therapeutic insight with specialist expertise, supported by a centralised leadership structure which keeps decision-making efficient and focused. Designed for small and mid-size drug developers, we build scalable, tailor-made solutions which adapt to your project needs. Get in touch with us today and gain a partner aligned to your goals and driven by the same purpose: advancing meaningful therapies which improve patients’ lives.